

# CIRSE 2024 Lisbon, Portugal September 14-18

## **Embolization: particulate agents**

## **Coordinators:**

Carolina Lanza, Daniel Torres

## Participating corporate partners:

Boston Scientific

Merit Medical

Sirtex Medical

Terumo

Varian

There are a variety of different similar products for this procedure beyond the ones demonstrated in this session.



# Particles & SIRT – CIRSE 2024



#### DC Bead & DC Bead LUMI



### **Compatibility & Drug Elution Profile**

- BSC mCath Family Compatibility
  - ✓ Size Distribution Consistency No aggregation in cath
  - ✓ Compresibility and Re-gain shape
- **☐** Drug Elution Profile
  - ✓ Both DC Bead™ and DC Bead LUMI™ demonstrate controlled and prolonged release profiles
- □ Radiopacity of LUMI™
  - ✓ Persistent visibility of LUMI at 6 week follow-up
  - ✓ Marking to guide future interventions

#### Precise, Proven, and Personalized



#### **PROVEN**

TheraSphere is the only SIRT backed by level-1 evidence in both HCC and CLM.<sup>1-2</sup> It has demonstrated success in a range of scenarios: Curative intent or palliative treatment, livers with single or multifocal tumours, portal vein thrombosis (PVT).<sup>1-8</sup>

#### **PERSONALISED**

A truly personalised therapy option for patients with options to select the activity you need to achieve your intended dose and treatment outcome.

#### **PRECISE**

Precise formulation enables highly concentrated radioactivity per microsphere to deliver a maximal prescribed dose every time.

### **SimplicitY & TheraSphere Now**



EASY-TO-USE SOFTWARE DESIGNED TO ACCELERATE THERASPHERE DOSIMETRY PLANNING AND IMPROVE Y-90 WORKFLOWS





Web-based ordering to facilitate easier TheraSphere treatment ordering, tracking, and management

# **Embolics - Merit portfolio**

## Embosphere®

Microspheres



#### Class 2B, Trisacryl, 7 sizes

- Over 250 clinical articles
- Predictable
- Fast and stable endpoint
- · Inert, low inflammatory profile
- Most published spherical embolic in UFE & PAE





- First gelatin foam <u>indicated for</u> <u>intra-arterial use</u>
- Can be delivered through catheters and microcatheters
- Slurry/Cube injection: The choice is yours!





#### Class 3A, copolymer

- Indicated for use with Doxo & Irinotecan in TACE
- 1 vial / procedure
- Conformable optimal Embo & Drug delivery
- High Objective Tumour Response
- Reduced pain & complications
- Over 50 publications
- 15 days stability (loaded)



**Embolization Particles** 



- Particles made of polyvinyl alcohol intended for the embolization of peripheral hyper vascularized tumors, including uterine fibroids and peripheral AVMs.
- Bearing nsPVA is a long-term implantable device used to permanently occlude blood vessels



## **TERUMO PARTICULATE AGENTS PORTFOLIO**



- Loadable with 4 chemotherapeutic drugs Doxorubicin, Idarubicin, Epirubicin and Irinotecan
- ◆ Veloso et al published new standard in DEM-TACE overall survival with a 580 unresectable HCC patients cohort analysis with a median overall survival of 50.8 months¹.



## **BioPearl**

- First resorbable drugeluting microspheres
- Progressive blood flow restoration<sup>2</sup>
- Sustained chemotherapeutic drug release (in-vitro)<sup>3</sup>
- ◆ Embolic effect<sup>2</sup>

# QuiremSpheres Holmium-166 Microspheres

QuiremScout

Holmium-166 Microspheres

Tommann 100 mmer copiner co

Q-Suite

**Imaging Software** 

- ◆ The Holmium Platform: Three integrated products delivering individualized SIRT at its' full potential
  - ◆ QuiremScout® is the first and only CEmarked SIRT work-up product that utilizes the same technology as the therapeutic microspheres which aims to optimize patient selection and advance treatment planning
  - QuiremSpheres® Holmium-166 SIRT microspheres for the treatment of liver cancer





2. Data on file: TR18-174B – BioPearl Liver studies

3. BioPearl IFU: IFU100073 Rev. B 2020-03

